Previous Page  12 / 40 Next Page
Information
Show Menu
Previous Page 12 / 40 Next Page
Page Background

Disposition of Patients Completing <br />≥94 Weeks of Pembrolizumab Treatment

Presented By Georgina Long at 2018 ASCO Annual Meeting